Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded on a mission to discover, develop and commercialize innovative, first-in-class medicines that address significant unmet medical needs, today announced it will hold a conference call on Thursday, October 30, 2025 at 4:30 PM Eastern Time to discuss financial results and provide a third quarter business update from 2025.
To join the conference call, call (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask if you would like to join the Ardelyx call. Live audio of the conference call will be simultaneously webcast and available under the Investors section of the Company’s website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days after the call.
About Ardelyx
Ardelyx was founded with the mission to discover, develop and commercialize innovative, first-in-class medicines that address significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). Ardelyx has agreements to develop and commercialize tenapanor outside the US. Kyowa Kirin commercializes PHOZEVEL ® (tenapanor) for hyperphosphatemia in Japan. A new drug application for tenapanor for hyperphosphatemia has been approved in China by Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, visit https://ardelyx.com/ and contact us X (formerly known as Twitter) , LinkedIn And Facebook .
Investor and media contacts:
Caitlin Lowie
clowie@ardelyx.com
#Ardelyx #reports #quarter #financial #results #October